William Blair analyst Andy Hsieh maintained a Buy rating on Nektar Therapeutics (NKTR) on February 17. The company’s shares closed last Friday at $25.10, close to its 52-week high of $26.75.
According to TipRanks.com, Hsieh is a 4-star analyst with an average return of 24.5% and a 62.4% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Viking Therapeutics, and Beyondspring.
Nektar Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $29.25, representing a 17.0% upside. In a report issued on February 17, Piper Sandler also maintained a Buy rating on the stock with a $35.00 price target.
See today’s analyst top recommended stocks >>
Nektar Therapeutics’ market cap is currently $4.49B and has a P/E ratio of -10.30. The company has a Price to Book ratio of 4.17.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The company focuses on the therapies for cancer, autoimmune disease, and chronic pain. It operates through the United States and Europe geographical segments. The company was founded in 1990 and is headquartered in San Francisco, CA.
